Company Update (NASDAQ:CELG): Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Beta-Thalassemia Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

[Business Wire] – Celgene Corporation and Acceleron Pharma Inc. today announced preliminary results from two Phase 2 clinical trials of luspatercept in patients with beta-thalassemia were presented at the 57th American Society of . . . → Read More: Company Update (NASDAQ:CELG): Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Beta-Thalassemia Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition Similar Articles: Company Update (NASDAQ:CELG): Celgene Reports Third Quarter 2015 Operating and Financial Results Market Update (NASDAQ:CELG): Celgene Corporation Commences Tender Offer for Receptos, Inc. Company Update (NASDAQ:CELG): Robbins Arroyo LLP: Acquisition of Receptos, Inc. (RCPT) by Celgene Corporation (CELG) May Not Be in Shareholders’ Best Interests